UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


WASHINGTON, D.C. 20549








FORM 10-Q





(Mark One)


TQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the Quarterly Period Ended March 31, 2011


Or


£TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromto





Commission file number: 000 – 52077


MEDPRO SAFETY PRODUCTS, INC.


(Exact name of registrant as specified in its charter)


Nevada91-2015980(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)145 Rose Street, Lexington, KY40507(Address of principal executive offices)(Zip Code)


(859) 225-5375


(Registrant’s telephone number, including area code)








Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.


Yes T No £


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes £ No £


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer £ Accelerated filer £


Non-accelerated filer £ Smaller reporting company T


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes £ No T


Indicate the number of shares outstanding of each of the issuer’s class of common stock, as of the latest practicable date, 12,984,216 shares of Common Stock were outstanding at May 11, 2011.








---




INDEX





PagePART I –FINANCIAL INFORMATION3ITEM 1.FINANCIAL STATEMENTS3ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS20ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK25ITEM 4.CONTROLS AND PROCEDURES25PART II –OTHER INFORMATION25ITEM 1.LEGAL PROCEEDINGS25ITEM 1A.RISK FACTORS25ITEM 2.UNREGISTERED SALES ON EQUITY SECURITIES AND USE OF PROCEEDS26ITEM 3.DEFAULTS UPON SENIOR SECURITIES26ITEM 4.RESERVED26ITEM 5.OTHER INFORMATION26ITEM 6.EXHIBITSAND FINANCIAL STATEMENT SCHEDULES27








2


---




PART I





Item 1. Financial Statements





The following financial statements of MedPro Safety Products, Inc. are included:





Balance Sheets as of March 31, 2011 and December 31, 2010





Statements of Operations for the three months ended March 31, 2011 and 2010





Statements of Changes in Shareholders’ Equity for the three months ended March 31, 2011 and the year ended December 31, 2010





Statements of Cash Flows for the three months ended March 31, 2011 and 2010





Notes to Unaudited Financial Statements











3


---




MedPro Safety Products, Inc.


Balance Sheets


March 31, 2011 and December 31, 2010





March 31, 2011December 31, 2010(Unaudited)ASSETSCurrent AssetsCash and cash equivalents$13,640,917$8,315,644Restricted cash2,959,1883,864,411Accounts receivable176,513179,107Accrued interest income2,0463,898Prepaid expenses and other current assets25,45629,368Escrowed Senior Note funds—7,870,000Total current assets16,804,12020,262,428Property and EquipmentEquipment and tooling973,875887,607Leasehold improvements768,478240,411Computers, network and phones211,172210,816Furniture and fixtures140,379117,896Trade show booth7,3417,3412,101,2451,464,071Less: accumulated depreciation380,468422,586Property and equipment, net1,720,7771,041,485Other AssetsIntangible assets, net of amortization of $723,109 and $596,839, respectively8,191,5408,317,810Deferred financing costs, net of amortization of $280,389 and $157,291, respectively1,764,1111,887,210Prepaid royalties100,000100,000Total other assets10,055,65110,305,020Total assets$28,580,548$31,608,933





See notes to financial statements.




















4


---




MedPro Safety Products, Inc.


Balance Sheets (Continued)


March 31, 2011 and December 31, 2010





March 31, 2011December 31, 2010(Unaudited)LIABILITIES AND SHAREHOLDERS’ EQUITYCurrent LiabilitiesAccounts payable and accrued expenses$936,989$762,523Accrued interest payable700,000700,000Derivative liabilities – fair value of warrants756,5261,157,823Total current liabilities2,393,5152,620,346Long-Term LiabilitiesSenior Notes30,000,00030,000,000Total long-term liabilities30,000,00030,000,000Total liabilities32,393,51532,620,346Shareholders’ EquityPreferred stock $.01 par value: 10,000,000 shares authorized:Series A Preferred 6,668,229 shares issued and outstanding.  Liquidation preference $1,970,077 and $1,820,829, respectively66,68266,682Series B Preferred 1,493,779 shares issued and outstanding14,93714,937Series C Preferred 1,571,523 shares issued and outstanding15,71515,715Common stock $.001 par value; 90,000,000 shares authorized; 13,022,126 and 13,091,507 issued and outstanding, respectively13,02213,092Additional paid-in capital71,276,31871,344,241Accumulated deficit(75,199,641)(72,466,080)Total shareholders’ deficiency(3,812,967)(1,011,413)Total liabilities and shareholders’ deficiency$28,580,548$31,608,933





See notes to financial statements.








5


---




MedPro Safety Products, Inc.


Statements of Operations


For the Three Months Ended March 31, 2011 and 2010





For the Three Months EndedFor the Three Months EndedMarch 31, 2011March 31, 2010(Unaudited)(Unaudited)RevenuesProduct Royalty Income$150,000$—Total revenue150,000—Cost of revenues and amortization of intellectual property135,168—Gross profit14,832—Operating ExpensesSalaries, wages, and payroll taxes827,0452,263,950Qualified profit sharing plan14,02014,436Advertising and promotion38,049190,436Product development costs247,452210,021Professional and insurance450,812483,251General and administrative136,16874,645Travel and entertainment74,755127,749Loss on disposal of assets144,114—Depreciation and amortization49,679162,255Total operating expenses1,982,0943,526,743Loss from operations(1,967,262)(3,526,743)Other Income (Expenses)Interest expense - including amortization of financing costs of $123,098 and $10,443(1,173,098)(61,796)Interest income5,5026,901Change in fair value of derivative liabilities401,29742,928Total other income /(expenses)(766,299)(11,967)Provision for income taxes——Net (loss)$(2,733,561)$(3,538,710)Net (loss) per common shareBasic net (loss) per share$(0.21)$(0.27)Fully diluted net (loss) per share$(0.21)$(0.27)Shares used in computing earnings per shareWeighted average number of sharesoutstanding - basic13,059,49213,215,311Weighted average number of shares outstanding - diluted13,059,49213,215,311


See notes to financial statements.





6


---




MedPro Safety Products, Inc.


Statements of Shareholders’ Equity


For the Three Months Ended March 31, 2011


and the Year Ended December 31, 2010








Common StockPreferred StockUnearnedPaid-InAccumulatedSharesAmountSharesAmountCompensationCapitalDeficiencyBalance, January 1, 201013,215,311$13,2159,733,531$97,334$(167,600)$67,023,700$(56,951,866)Earned portion of vendor share-based compensation————167,600——Earned portion of employee and director options—————4,824,853—Deivative liabilities - warrants issued with debt—————(844,488)—Derivative liability discount accretion—————685,000—Purchases of common shares(123,804)(123)———(344,824)—Net (loss)——————(15,514,214)Balance December 31, 201013,091,507$13,0929,733,531$97,334$—$71,344,241$(72,466,080)Earned portion of employee and director options—————95,577—Purchases of common shares(69,381)(70)———(163,500)—Net (loss)——————(2,733,561)Balance, March 31, 201113,022,126$13,0229,733,531$97,334$—$71,276,318$(75,199,641)





See notes to financial statements.





7


---




MedPro Safety Products, Inc.


Statements of Cash Flows


For the Three Months Ended March 31, 2011 and 2010





March 31, 2011March 31, 2010(Unaudited)(Unaudited)Cash Flows From Operating ActivitiesNet (loss)$(2,733,561)$(3,538,710)Adjustments to reconcile net (loss) to net cashflows from operating activities:Depreciation49,67935,984Amortization249,369136,714Loss on disposal of assets144,114—Share based compensation95,5772,039,435Change in fair value of warrant (derivative liabilities)(401,297)(42,928)Changes in operating assets and liabilitiesAccounts receivable and accrued interest4,446(6,191)Inventory—(5,031)Other current assets3,9125,657Accounts payable and accrued expenses174,46576,356Net cash flows from operating activities(2,413,296)(1,298,714)Cash Flows From Investing ActivitiesPurchases of property, equipment and intangibles(873,085)(41,189)Restricted cash-Interest Reserve905,223—Net cash flows from investing activities32,138(41,189)Cash Flows From Financing ActivitiesTechnology transfer payments—(250,000)Repayments on bank borrowings—(442,144)Proceeds from notes payable to and advances from shareholders—1,300,000Senior Note funds released from escrow7,870,000—Repurchases of common shares(163,569)—Net cash flows from financing activities7,706,431607,856Net increase / (decrease) in cash5,325,273(732,047)Cash at the beginning of the period8,315,6444,072,443Cash at the end of the period$13,640,917$3,340,396Supplemental Disclosures of Cash Flow Information:Cash paid for interest$1,050,000$47,646Non-Cash ActivityNon-cash portion of derivative liabilities associated with warrants$401,297$412,956


See notes to financial statements.











8


---




MedPro Safety Products, Inc.


Notes to Financial Statements


(Unaudited)





NOTE 1 – BASIS OF PRESENTATION





The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.  In the opinion of management, all adjustments (consisting of only normal recurring accruals) considered necessary for a fair presentation have been included.  Operating results for the three months ended March 31, 2011 are not necessarily indicative of the results that may be expected for the year ended December 31, 2011 .  For further information, refer to the Company’s financial statements and footnotes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2010 .





NOTE 2 – INCOME TAXES





Income tax expense is provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due plus deferred taxes.  Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes.  The differences relate primarily to the effects of net operating loss carry forwards and differing basis, depreciation methods, and lives of depreciable assets. The deferred tax assets represent the future tax return consequences of those differences, which will be deductible when the assets are recovered.





No income tax benefit (expense) was recognized for the three months ended March 31, 2011 as a result of tax losses in this period and because deferred tax benefits, derived from the Company’s prior net operating losses, were previously fully reserved and the Company has cumulative net operating losses for tax purposes in excess of $29 million.





The Company currently has tax return periods open beginning with December 31, 2007 through December 31, 2010.





NOTE 3 – EARNINGS PER SHARE





In accordance with Statement of Financial Accounting Standards (SFAS) No. 128, “Earnings Per Share”, which was primarily codified into ASC Topic 260, basic earnings per share were computed using weighted average shareholdings of 13,059,492 and 13,215,311 for the three months ended March 31, 2011 and 2010 .  There were no new common shares issued in the three months ended March 31, 2011 and March 31, 2010.





The basic earnings per share are calculated on the weighted average number of common shares outstanding.  Diluted earnings per share are based on the weighted average number of common shares outstanding and all dilutive potential common shares outstanding.  Because the Company had a net loss for the three month period ended March 31, 2011 and 2010, there is no dilutive effect and both the basic and diluted losses per share were the same for this period.





Basic earnings / (loss) per common share represents the amount of earnings / (loss) for the period available to each share of common stock outstanding during the reporting period.  Diluted earnings (loss) per common share is the amount of earnings (loss) for the period available to each share of common stock outstanding during the reporting period and to each share that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares outstanding during the period.





The Company’s potentially dilutive securities consist of options and warrants, as well as, convertible preferred stock.  Since the Company had a loss in 2011 and 2010, the potentially dilutive options, warrants and preferred shares were not considered and earnings per share were only presented on a non dilutive basis.





NOTE 4 - RECENT ACCOUNTING PRONOUNCEMENTS





Recent Accounting Pronouncements





Adopted





In April 2010, the FASB issued ASU 2010-17   Revenue Recognition-Milestone Method (Topic 605). The update is intended to assist with the definition of a milestone event and determining when the application of milestone revenue recognition in


9


---

NOTE 4 - RECENT ACCOUNTING PRONOUNCEMENTS - Continued,


connection with revenue recognition for research and development transaction. Disclosures will include the description of the milestone payment arrangement, a description of each milestone and the related payment or contingent payment, a determination whether the milestones are substantive, the factors considered in making the determination of the substantive nature of the milestones and the amount of revenue recognized during the period related to the milestone or milestones.  The standard is effective for fiscal years beginning on or after June 15, 2010.  The Company has adopted the standard but does not currently have any such contracts.  The adoption of the standard has not had a material impact on its financial statements.





In April 2010 the FASB issued update  ASU 2010-17, Revenue Recognition - Milestone Method (Topic 605), which had as a major objective, guidance on the revenue recognition for vendors providing research and development deliverables under a contract or arrangement having one or more payments contingent upon achieving uncertain future events or circumstances.





In January 2010, the FASB issued ASU, 2010-06, Fair Value Measurement and Disclosures (Topic 820-10-65-7), which relates to the disclosure requirements for fair value measurements and provides clarification for existing disclosures requirements. This update will require an entity to disclose separately the amounts of significant transfers in and out of Levels 1 and 2 fair value measurements and to describe the reasons for the transfers.  It also will require entities to disclose information about purchases, sales, issuances and settlements to be presented separately (i.e. present the activity on a gross basis rather than net) in the reconciliation for fair value measurements using significant unobservable inputs (Level 3 inputs). This guidance clarifies existing disclosure requirements for the level of disaggregation used for classes of assets and liabilities measured at fair value and requires disclosures about the valuation techniques and inputs used to measure fair value for both recurring and nonrecurring fair value measurements using Level 2 and Level 3 inputs. The new disclosures and clarifications of existing disclosure are effective for fiscal years beginning after December 15, 2009, except for the disclosure requirements related to the purchases, sales, issuances and settlements in the roll forward activity of Level 3 fair value measurements.  Those disclosure requirements are effective for fiscal years ending after December 31, 2010. The adoption of the disclosure requirement did not have a material impact on the Company's financial statements.





In 2010, the FASB issued ASU 2010-28, Intangibles-Goodwill and Other (Topic 350): When to Perform Step 2 of the Goodwill Impairment Test for Reporting Units with Zero or Negative Carrying Amounts .  It is effective for fiscal years beginning after December 15, 2010.  Essentially the FASB is requiring testing be performed at the Reporting Unit level with zero or negative carrying amounts.  For goodwill and other intangible assets, testing for impairment is a two-step test.  When a goodwill impairment test is performed (either on an annual or interim basis), an entity must assess whether the carrying amount of a reporting unit exceeds its fair value (Step 1).  If it does, an entity must perform an additional test to determine whether goodwill has been impaired and to calculate the amount of that impairment (Step 2).  The effect will potentially be an impairment of goodwill or other intangibles will be required to be reported sooner than under current standards.  The Company has adopted the standard but does not have any negative goodwill issues.  Therefore, the adoption did not have a material impact on the Company's financial statements.





In October 2009, the FASB issued new accounting guidance (Accounting Standards Update (ASU), 2009-13) related to revenue arrangements with multiple deliverables, Revenue Recognition (“Topic 605-25-65-1”): Multiple Deliverable Revenue Arrangements - A Consensus of the FASB Emerging Issues Task Force , that provides principles for allocation of consideration among an arrangement's multiple-elements, allowing more flexibility in identifying and accounting for separate deliverables. The guidance introduces an estimated selling price method for valuing the elements of a bundled arrangement if vendor-specific objective evidence or third-party evidence of selling price is not available, and significantly expands related disclosure requirements. This guidance is effective on a prospective basis for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010.  Alternatively, adoption may be on a retrospective basis, and early application is permitted. We have adopted this standard but it has not had a material impact on our financial statements.





The Company has adopted this update but has no recorded goodwill and impairment of intangibles, as a result of adoption, has not had a material effect on the financial statements.





In April 2010, the FASB issued ASU 2010-12 - Income Taxes (Topic 740) Accounting for Certain Tax Effects of the 2010 Health Care Reform Acts .  This updates makes it clear that the two laws passed a few days apart and commonly known as health care reform will be treated as one for accounting purposes despite the fact that they may have been passed in two different fiscal years for some.  Our adoption of ASU 2010-12 did not have a material impact on our financial statements.





In January 2010, the FASB adopted ASU 2010-06 - Fair Value Measurements and Disclosures - Improving Disclosures about


Fair Value Measurements (Topic 820).  This statement enhances disclosure relating to recurring or nonrecurring fair value measurement, specifically transfers between Level 1 and Level 2 inputs and the reasons for such transfers, the Level 3 activity reporting information on a gross rather than a net basis and improved guidance about disclosure by classes of assets and


10


---

NOTE 4 - RECENT ACCOUNTING PRONOUNCEMENTS - Continued,


liabilities.  Also disclosure should include the various inputs and techniques used for valuation of assets and liabilities.  We have adopted this statement and the enhanced disclosure in our financial statements.





Reclassifications





Certain amounts in the 2010 financial statements have been reclassified to conform to the classifications used to prepare the 2011 financial statements.  These reclassifications had no material impact on the Company’s financial position, results of operations, or cash flow as previously reported.





NOTE 5 – INVENTORY





The Company had no inventory at December 31, 2010 or March 31, 2011.  The former Needlyzer inventory was completely disposed of in late 2010.  The Company maintains no inventory of finished goods for sale.  The cost of materials and supplies purchased for testing prototype products is expensed as research and development.





NOTE 6 – INTANGIBLE ASSETS





The Company’s intangible assets consist primarily of intellectual properties (medical device patents) that give the Company the right to produce and exploit certain medical devices commercially.  The various patents include the skin and tube-activated blood collection devices with a cost of $2,525,425, the Key-LokTM patent at an original cost of $489,122, the syringe guard prefilled family of products at $4,845,000 and the winged infusion set at $1,250,000.  The Company also has $2,044,500 of loan fees recorded as intangible assets.





During the third quarter of 2010, the Company paid off all bank borrowings and thus fully amortized the original loans fees of $183,333.  New loan fees of $2,044,500 were recorded as of  October 1, 2010.  These fees are being amortized over the term of our Senior Notes, which ends October 30, 2016.  Amortization began when the respective Senior Notes were issued.  The fees are being amortized under a yield method based on the relative outstanding principal of the Senior Notes.





To date, three of the existing patented products, the blood collection devices, the winged blood collection set and the syringe guard products, have been utilized to manufacture parts for testing and evaluation.  The Company's customer and manufacturer began delivering the Tube-TouchTM blood collection device in the second quarter of 2011.  The Company has earned royalty revenue, based on minimum production volumes, for the last two calendar quarters.





Amortization expense of $249,368 includes amortization of $126,271 for the intellectual property and amortization of loan fees of $123,097.  Estimated future amortization for the balance of this fiscal year is expected to be $748,104 (financing costs $369,292 and intellectual property $378,812).  The following amounts of amortization for the fiscal years ended on December 31 are expected to be as follows:





Fiscal Year EndingDecember 31,Intellectual PropertyAmountFinancing CostsAmount2012$1,724,085$492,3902013$1,724,085$432,3272014$1,681,995$320,1552015$1,219,000$137,638After 12/31/2015$1,219,000$12,309





11


---




NOTE 7 – LONG-TERM DEBT





Long-term debt at March 31, 2011 and December 31, 2010 consisted of the following:





March 31, 2011December 31, 201014% Senior Notes due 2016 to various noteholders, interest due quarterly beginning October 31, 2010, principal payments commence when revenue from the guaranteed minimum volume contract is sufficient to cover principal and interest; 100% of the contract revenue, reduced by certain limited expenses, is allocated to debt service through October 30, 2016$30,000,000$30,000,00030,000,00030,000,000Less: current portion——Long-term portion$30,000,000$30,000,000





There are no maturities of long-term debt for the remainder of this fiscal year.  The following table summarizes the estimates maturities of long-term debt for the fiscal years ended December 31:





Fiscal Year Ended December 312012$—2013$5,606,0292014$7,957,3172015$13,254,3292016$3,182,325





The Company issued $30,000,000 of 14% Senior Secured Notes due 2016 in two tranches on September 1 and October 1, 2010.  Gross proceeds from the issuance of the Notes were reduced by $2,044,500 of issuance costs, payment of $121,000 of legal fees of the investors and the trustee, $4,500,000 to fund an interest reserve and $7,870,000 set aside in a reserve payable to the Company upon the receipt of FDA clearance for the Wing device.  FDA clearance on the Wing device was received in November 2010, and on January 30, 2011, the $7,870,000 in escrowed funds, plus interest, were released to the Company.





The interest reserve is to be used to pay interest during the ramp up of royalty payments due on the blood collection devices under our minimum volume contracts.  The first payment on the notes of $630,000 was paid on October 30, 2010.  Royalty revenues received under the GBO agreement are deposited into a collection account held by the trustee, and these funds are supplemented from the interest reserve, as necessary, to complete the scheduled payments on the Notes.  The next four quarterly payments on the Notes are scheduled to be $1,050,000 per quarter.  The balance in the interest reserve account at December 31, 2010 was $3,864,411, which is less than the total amount of payments due in the next twelve months.  Accordingly, the Company classified the entire balance of the restricted cash account as a current asset.  However, because royalties increase as minimum product purchases increase over the term of the GBO agreement, the full amount of the interest reserve account is not expected to be used to pay the entire interest payments on the Notes during the next twelve months.  Payments of principal and interest to the Noteholders are guaranteed by the Company.  The balance in the interest reserve (restricted cash) account at March 31, 2011 was $2,959,188.








The use of proceeds from the Senior Notes is presented in tabular form below:





12


---

NOTE 7 - LONG TERM DEBT - Continued,


Source and Use of FundsAmountProceeds from Sale of Senior Notes$30,000,000Expenses not amortized(162,358)Amortizable loan fees and expenses(2,044,500)Reserve for interest payments(4,500,000)Net proceeds to Company$23,293,142Reserve for FDA product clearance (funded by Company)(7,870,000)Pay off  bank debt and shareholder bridge loans(4,112,967)Net proceeds after FDA reserve and debt repayment$11,310,175





The funds held in the reserve pending FDA product clearance were released to the Company on January 30, 2011.  Net proceeds, including the FDA Reserve funds, totaled $19,180,175





Royalty collections through October 30, 2016 are allocated to the payment of principal and interest on the Notes.   Once principal is paid down to $1,000,000, additional interest is paid to the Note holders based on cash flow under the contract.  The final $1,000,000 of principal is paid with the last payment on the Notes.  Any payments made in 2016 are reduced by the marketing assistance payments due to our customer under the minimum volume contract.  The amount of the Company's  marketing assistance payments are payable from the royalties.  The Company is also entitled to receive a servicing fee of $5,000 per quarter, plus out of pocket expenses, subject to quarterly limitations.





The Note covenants restrict additional senior borrowing to $7,500,000 and new subordinated debt to $15,000,000.








NOTE 8 – NOTES PAYABLE TO AND ADVANCES TO/ FROM SHAREHOLDERS





2010 VOMF Bridge Loans





During 2010, MedPro borrowed a total of $2,800,000 from VOMF in short-term bridge loans.  MedPro issued warrants to purchase common stock as consideration for the bridge loans.  The following table provides certain information about each bridge loan.





DatePrincipalAmountInterest RateShares subject to WarrantsExercise Priceper shareFebruary 8, 2010$500,0006%——February 26, 2010350,0006%212,500$4.00March 31, 2010450,0006%112,5004.00May 4, 2010250,0007%208,3343.00May 28, 2010300,0007%50,0013.00June 30, 2010450,0007%75,0023.00August 5, 2010500,0007%83,3353.00Total$2,800,000741,672





The $2,800,000 outstanding principal balance of the VOMF bridge loans plus accrued interest of $57,214 was paid in full on September 1, 2010. Previously recorded loan discount, accumulating to $685,000, was expensed as interest when the loans were paid.





13


---

NOTE 9 – RELATED PARTY TRANSACTIONS





On March 6, 2008, the Company entered into a consulting agreement with SC Capital Partners, LLC to assist it with future capital requirements, strategic financial planning and support of the Company’s efforts to build shareholder liquidity.  The contract was superseded by a new contract on January 11, 2010.  The agreement calls for a retainer of $15,000 per month, plus out-of-pocket expenses, beginning on the date of execution.  The agreement may be terminated by the Company with appropriate notice or upon satisfaction of the goals of the agreement.  The agreement also contains certain fees for future capital milestones achieved.  Warren Rustand, a director of the Company, is a principal of SC Capital.





The Company also issued Series AA warrants to purchase 533,458 common shares for $1.81 per share as compensation for financial advisory services provided by SC Capital in connection with the December 28, 2007 private placement.  The terms of these warrants are comparable to the terms of the “A” warrants and they expire on December 28, 2012.  None of the AA warrants have been exercised as of the date of the financial statements.





As a part of the issuance of the Senior Notes on September 1, 2010, SC Capital earned a fee of $500,000.   When the second tranche closed on October 1, 2010, SC Capital earned an additional $100,000 fee.





NOTE 10 – SHAREHOLDERS’ EQUITY





The Company is authorized to issue 90,000,000 shares of common stock with a par value of $0.001 per share, and 10,000,000 shares of preferred stock with a par value of $.01 per share, which is issuable in series.  Of the 10,000,000 shares of preferred stock authorized, 6,668,229 shares are designated as Series A Convertible Preferred Stock (“Series A Stock”), 1,493,779 shares are designated as Series B Convertible Preferred Stock (“Series B Stock”) and 1,571,523 shares are designated as Series C Convertible Preferred Stock (“Series C Stock”).





At March 31, 2011 , the Company’s issued and outstanding shares consisted of 13,022,126 shares of common stock, 6,668,229 shares of Series A Stock, 1,493,779 shares of Series B Stock, and 1,571,523 shares of Series C Stock.  In addition, warrants to purchase 2,476,012 shares of common and options to purchase 4,208,471 shares of common were outstanding at March 31, 2011 .





See Note 12 of the notes to our audited financial statements included in our Annual Report on Form 10-K for 2010 for a detailed description of the terms of our three series of preferred stock and stock purchase warrants issued and outstanding, including the accounting treatment.





The Company had previously authorized the issuance of warrants to purchase up to 68,036 common shares for $1.99 per share as compensation for the publication of a research report about the Company in a medical device industry publication.  These warrants became exercisable when the report was delivered to the Company and will expire on December 28, 2012.  During 2009, the Company and the warrant holder negotiated a settlement of a disagreement resulting in the issuance of an additional 31,964 warrants under the original terms and 75,000 warrants exercisable under the original timing but at the market price of $3.75 per share at the date of issuance.  We expensed the unearned portion of these warrants in the first quarter of 2010.





On June 25, 2009, the Company announced that its Board of Directors had authorized the repurchase of up to one million shares of the Company’s common stock.  Through December 31, 2010 the Company had repurchased 228,884 shares in open market transactions at an average price per share of $3.20.  None of these purchases occurred in the first quarter of 2010.  During the quarter ended March 31, 2011 , the Company acquired an additional 69,381 shares of its own common stock at an average price of $2.36.  The total number of shares repurchased has been 298,265 shares at $3.00 per share average cost.  The Company has spent $894,992 on share repurchases since the inception of the buy-back program.





NOTE 11 – STOCK PURCHASE WARRANTS





ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  ASC 820 establishes a fair value hierarchy that prioritizes the use of inputs used in valuation methodologies into the following three levels:


|  |                                                                                                                                                                                                                                           
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|• | Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.

|  |                                                                                                                                                                                                                                                       
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|• | Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable




14


---

market data.


|  |                                                                                                                                                                                                                                                                                                                             
|- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|• | Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.




The assets or liabilities fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. The Company's fair value measurements are designated as Level 3 since one of the significant inputs, the estimated term, cannot be derived from a Level 1 or Level 2 observable.





The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.





The following table sets forth by level, within the fair value hierarchy, the Company's liabilities at fair value as of March 31, 2011 (in thousands):





Derivative LiabilitiesLevel 1Level 2Level 3Balance at December 31, 2010$—$—$1,157,823Change in valuation for March 31, 2011——(401,297)Balance at March 31, 2011$—$—$756,526





All of the warrants we issued in 2010 provide for cashless exercise after one year.  In addition, if we issue any additional shares of common stock at a price per share less than the adjusted warrant exercise price then in effect or without consideration, then the exercise price will adjust to the price per share paid for the additional shares of common stock upon each such issuance.





The warrants we issued in the first quarter of 2010 had an exercise price of $4.00 per share.  As a result of the cashless exercise and anti-dilution features, the Company had recorded a liability for the fair market value of these warrants at their respective issue dates of $412,954.  The derivative liability was adjusted to $370,026 due to a $42,928 decline in the market value of the warrants as of March 31, 2010.





The inputs used to value the derivative liability as of the issue date of the respective warrants and at March 31, 2010 were:


|  |                                                                                                   
|- | --------------------------------------------------------------------------------------------------
|• | The market price of the Company’s stock on February 26, 2010 of $3.40 and March 31, 2010 of $3.10;

|  |                                                  
|- | -------------------------------------------------
|• | Specific Company Volatility for the quarter – 48%

|  |                             
|- | ----------------------------
|• | Risk free return rate – 2.3%

|  |                                         
|- | ----------------------------------------
|• | Estimated life of the warrants - 5 years




These inputs, coupled with the individual warrant exercise prices, resulted in a Black-Scholes value of $1.34 per share for the February 26, 2010 warrants and $1.14 per share for the March 31, 2010 warrants.  The $0.20201 per share decline in the 212,500 warrants from February 26, 2010 to March 31, 2010 resulted in a gain of $42,928 on the derivative liability as of March 31, 2010.





The warrants we issued in the second quarter of 2010 had an exercise price of $3.00 per share.  As a result of the cashless exercise and anti-dilution features, the Company had recorded a liability associated with these warrants at their respective issue dates of $410,902.





The inputs used to value the derivative liability as of the issue date of the respective warrants and at June 30, 2010 were:


|  |                                                                                                                    
|- | -------------------------------------------------------------------------------------------------------------------
|• | The market price of the Company’s stock on April 30, 2010, June 3, 2010 and June 30, 2010 were all $3.00 per share;

|  |                                                                                                  
|- | -------------------------------------------------------------------------------------------------
|• | Specific Company Volatility for the valuation dates were 44.51%, 43.32% and 42.26%, respectively;

|  |                                                                      
|- | ---------------------------------------------------------------------
|• | Risk free return rates were 2.43%, 2.17% and 1.79%, respectively; and

15


---

|  |                                          
|- | -----------------------------------------
|• | Estimated life of the warrants - 5 years.




These inputs, coupled with the individual warrant exercise prices resulted in Black-Scholes per share values of approximately $1.25, $1.22 and $1.18 for the respective warrant grant dates.  The quarter end valuations of these warrants were determined based on a $3.00 market price, 42.26% volatility, 1.79% risk free return and estimated remaining lives of the warrant based on their respective maturity dates.





The warrants we issued in the third quarter of 2010 also have an exercise price of $3.00 per share.  As a result of the cashless exercise and anti-dilution features, the Company had recorded a liability associated with these warrants at their respective issue dates of $82,631.





The inputs used to value the derivative liability as of the issue date of the respective warrants and at September 30, 2010 were:


|  |                                                                               
|- | ------------------------------------------------------------------------------
|• | The market price of the Company’s stock on August 5, 2010 was $3.00 per share;

|  |                                                               
|- | --------------------------------------------------------------
|• | Specific Company Volatility for the valuation date was 34.79%;

|  |                                                                            
|- | ---------------------------------------------------------------------------
|• | Risk free return rate was 1.57% at issue date and 1.27% at quarter end; and

|  |                                          
|- | -----------------------------------------
|• | Estimated life of the warrants - 5 years.




These inputs, coupled with the individual warrant exercise prices resulted in a Black-Scholes value of approximately $0.99 per share for the warrant grant date.  The quarter end valuations of these warrants were determined based on a $3.00 market price, a 34.79% volatility, 1.27% risk free return and estimated remaining lives of the warrant based on their respective maturity dates.





NOTE 12 – STOCK OPTIONS





On August 18, 2008, the Company adopted the MedPro Safety Products, Inc. 2008 Stock and Incentive Compensation Plan (“2008 Plan”) and issued stock options to its directors and employees in the amounts and on the terms agreed upon in the September 2007 stock purchase agreement with the Series A Stockholders.  The Company’s employees, including its three executive officers, were granted a total of 2,800,000 options.  The two non-employee directors each were granted 100,000 options.  The options may be exercised at an exercise price of $1.81 per share only on the earliest of the 30 days following January 1, 2013, the date of the holder’s death or 100% disability, termination of employment or service as a director, and the date of a change in control of the Company.  Because the exercise price was less than market price of MedPro stock on the date of grant, the Company set a date certain for the exercise of the options in order to qualify for exemptions from excise taxes under IRS deferred compensation rules.





The Company recorded unearned compensation expense of $14,580,000, or $4.86 per underlying share, for the grant of these 3,000,000 options. The unearned compensation was being charged to earnings over 24 months beginning on August 18, 2008.  The 24 month period coincides with the term of a non-competition covenant included in the option agreement.  The balance of the unearned compensation of $951,750 was expensed in the third quarter of 2010.  Unearned compensation was fully amortized to expense in the third quarter of 2010.





On May 27, 2009, the Company awarded incentive stock options to purchase 185,715 common shares to all of its employees.  The exercise price of the options was $3.85 per share, the market price at the close of trading on the grant date, except that the exercise price for the options to purchase 25,974 shares awarded to the Company’s Chairman was $4.24, 110% of the market price, because he is a 10% shareholder.  The options are exercisable immediately and have a ten-year term, except for the Chairman’s options, which are limited to a five-year exercise term.  The Company recorded $355,106 of unearned compensation expense for the May 27, 2009 awards.  The Company is recording compensation expense over three different periods for the Chairman, other officers and other employees, respectively, at $5,819 per month. Unearned compensation for these options was $226,399 at March 31, 2011 .





The CEO’s options were valued based on a 2.5 year life with 1.23% risk-free return.  The other officer options were based on a 5 year life and a 2.43% risk-free return.  Finally, the employee options were based on a 6 year life and a 2.83% risk-free return.  The resulting values were $1.21, $1.90 and $2.09 per option, respectively, utilizing these inputs.





On August 24, 2009, the Company awarded options to purchase 50,000 shares to both of the directors appointed to its board in October 2008.  The options have the same terms as the options previously granted to the employees and the other directors in August 2008.  The option exercise price is $1.81 per share and the options may only be exercised between January 1, 2013 and January 31, 2013.  The unearned compensation booked at August 24, 2009 for these two options was $224,372. The Company


16


---

NOTE 12 – STOCK OPTIONS – Continued,


recorded compensation expense of $28,047 for the three months ended March 31, 2011.  The factors utilized to value these options were a volatility factor of 53%, a life of 2 years, $3.70 fair value at grant based on market prices and a1.05% risk-free rate of return.  The resulting option value based on the $1.81 exercise price was $2.24.  Unearned compensation for these options was $44,721 at March 31, 2011 .





On October 6, 2009, the Company awarded incentive stock options to purchase 47,256 common shares to its employees,


recorded compensation expense of $28,047 for the three months ended March 31, 2011.  The factors utilized to value these options were a volatility factor of 53%, a life of 2 years, $3.70 fair value at grant based on market prices and a1.05% risk-free rate of return.  The resulting option value based on the $1.81 exercise price was $2.24.  Unearned compensation for these options was $44,721 at March 31, 2011 .





On October 6, 2009, the Company awarded incentive stock options to purchase 47,256 common shares to its employees,


excluding officers.  The exercise price of the options was $3.65 per share, the market price at the close of trading on the grant


date.  The options are exercisable immediately and have a ten-year term. The Company recorded $91,944 of unearned compensation expense for the October 6, 2009 awards.





The unearned compensation is being recorded as expense over a six year life of the options at $1,277 per month. The Company recorded compensation expense of $3,831 for the three months ended March 31, 2011 .   The factors used to value these options were a life of 6 years, market prices for the stock value ($3.65 exercise price at date of grant), a 55% volatility factor and a 2.25% risk-free return.  The resulting value was $1.95 per option.  Unearned compensation on these options was $69,178 at March 31, 2011 .





On September 29, 2010, the Company awarded non-qualified stock options to purchase 575,000 common shares to its employees, including the COO and CFO, but excluding the CEO.  The exercise price of the options was $2.70 per share, the market price at the close of trading on the grant date.  The options are exercisable immediately and have a five-year term. The Company recorded $422,824 of unearned compensation expense for the September 29, 2010 awards.





The unearned compensation is being recorded as expense over a two and one-half year life for the officer options at $6,079 per month. The Company recorded compensation expense of $18,237 for the three month period ended March 31, 2011 .   The employee options are being recorded over five years at $4,065 per month.  The Company recorded $12,196 of earned compensation for the three months ended March 31, 2011 .





The factors used to value these options were a life of 2.5 and 5 years, market prices for the stock value ($2.70 exercise price at date of grant), a 34.79% volatility factor and a 0.67% and 1.28% risk-free return.  The resulting values were $0.60 and $0.88 per option, respectively for officers and employees.  Unearned compensation on these options was $361,626 at March 31, 2011 .





On February 2, 2011, the Compensation Committee of the Board awarded options to purchase 300,000 common shares to our CEO, one-third of the options vest on each of December 31, 2011, 2012 and 2013 provided our CEO continues to be employed by the Company on each vesting date.  The exercise price is $2.62 and the options have a five-year exercise period after they vest.  We calculated the value of these options using a 2.5 year exercise period after vesting and based the valuation on the Black-Scholes formula utilizing the following inputs:





Option VestsExpected Exercise DateOption TermPriceVolatilityRisk Free Return12/31/20116/30/20143.5$2.6272.148%1.12%12/31/20126/30/20154.5$2.6272.148%2.10%12/31/20136/30/20165.5$2.6272.148%2.10%














17


---

NOTE 12 – STOCK OPTIONS – Continued,


Based on the inputs, the options were valued as follows:





OptionValueAmortization of Earned Compensation at 3/31/2011Unearned Compensation at 3/31/201112/31/2011$132,103$6,053$126,05012/31/2012$149,822$5,307$144,51512/31/2013$162,750$4,697$158,053$444,675$16,057$428,618





The following table summarizes stock option activity for the periods indicated:


Three Months Ended March 31, 2011Twelve Months EndedDecember 31, 2010SharesAverage weighted exercise priceSharesAverage weighted exercise priceOutstanding  beginning of period3,908,471$2.063,332,971$1.95Granted300,000$2.62575,500$2.70Exercised————Expired/cancelled————Outstanding, end of Period4,208,471$2.103,908,471$2.06





The following table summarizes information about stock options outstanding and exercisable at March 31, 2011 :





Weighted average exercise priceOptionsoutstandingAverage weighted remaining contractual life (years)OptionsExercisable$2.104,208,4713.3841,108,471





NOTE 13 – LEASE COMMITMENT





With Related Party





The Company leased its office and storage facility in Lexington, Kentucky, under an operating lease with a related party.  On January 10, 2007, the Company signed a lease addendum that extended the term of the original 1998 lease through August 2012 with two five-year extension options.  The amended lease provides for lease payments of $3,500 per month from January 1, 2007, through July 31, 2007, and $6,500 per month from August 1, 2007, through January 31, 2008.  Beginning on February 1, 2008, the lease payment increased to $6,975 per month ($83,700 per year) for the remainder of the term when the Company increased its leased space by an additional 1,063 square feet.





Total lease expense was $20,925 for the three months ended March 31, 2011 and 2010 .  Future minimum lease payments for the balance of this fiscal year are expected to be $62,775 and $55,200 for the fiscal year ended December 31, 2012.





The Company recorded a loss of $144,114 in connection with the abandonment of leasehold improvements following its move to new offices on March 25, 2011.





Lease of New Office Space (Unrelated Party)





On October 29, 2010, the Company signed a lease on new office space to accommodate expected growth in staff over the next 12 to 18 months.  The new premises will cost the Company $8,000 per month rent, after a 90-day rent abatement period, and will continue for five years with three extensions of  three years each.  The lease may be terminated with a 90-day notice prior to the commencement of the third year and a payment of one year's rent ($96,000) as a termination fee.





Our existing space is being actively marketed but we may have to pay dual rent for a period of time until this space is rented.





18


---

NOTE 13 - LEASE COMMITMENT - Continued,


Lease expense on the new premises began on May 1, 2011.  There was no rent expense in the first quarter of 2011 on the new offices.  Future minimum lease payments for the balance of this fiscal year are expected to be $64,000 and for future annual fiscal periods ended December 31 are as follows:





Fiscal Year EndedDecember 31,2012$96,000201396,000201496,000201596,00020168,000Total$392,000








NOTE 14 – DEVELOPMENT AND DISTRIBUTION AGREEMENTS





Joint Development Agreement





On March 8, 2010, the Company entered into a Joint Development Agreement with a worldwide manufacturer of rubber closures and aluminum and plastic caps for pharmaceutical packaging, drug delivery and diagnostics.  The joint development agreement establishes the respective responsibilities and contributions of the parties in connection with the development and distribution of our pre-filled passive safety syringe system.





The agreement provides that we will develop the safety syringe portion of the pre-filled passive safety syringe system, and the co-venturer will develop rubber components for the product, including determining the appropriate chemical rubber formulation and component design for use with the medicament cartridge. The agreement also establishes a general framework for formalizing the role of additional participants in the project.





Distribution Agreements





On July 16, 2010, we entered into a new agreement with an international manufacturer and supplier of medical products through its worldwide distribution network.   The agreement grants the distributor the right to manufacture, market and distribute MedPro’s tube-activated and skin-activated blood collection systems and its winged blood collection set and terminates and supersedes the two prior agreements.  The July 2010 Agreement has a term ending six years from October 1, 2010, which may be extended for up to three years in certain circumstances.





During the term of the July 2010 Agreement, the distributor will pay a total minimum royalty of not less than $43,750,000 (the “Royalty Amount”).  Royalty payments will be made no later than the fifteenth day following the end of each calendar quarter, based on a minimum number of units for each calendar quarter.  Until the Royalty Amount has been paid in full, if the aggregate royalties paid for all preceding quarters in the aggregate exceeds the minimum aggregate royalties owed on minimum quarterly production for all preceding quarters, then the minimum royalty obligation for the next quarter will be reduced accordingly.





The Company agreed to make a quarterly financial contribution to the distributor to help cover the anticipated expenses of marketing the products once production has begun.  Our marketing contributions would total approximately $6.65 million over the six-year term of the July 2010 Agreement.  The Company also agreed to pay the distributor $350,000 to resolve issues of prior agreements.











19


---







Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations





The following discussion and analysis of the financial condition and results of operations of MedPro Safety Products, Inc. as of and for the three months ended March 31, 2011 should be read in conjunction with our audited financial statements and the notes to those financial statements that are included elsewhere in this report or our annual filings of Form 10K for 2010.  References in this Management’s Discussion and Analysis or Plan of Operations to “us,” “we,” “our,” and similar terms refers to MedPro Safety Products, Inc.





Preliminary Note Regarding Forward-Looking Statements





This report contains statements about future expectations, activities and events that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of our future financial and operating performance and growth plans, taking into account the information currently available to us. Any statements that are not statements of historical fact are forward-looking statements. Words such as “believe,” “may,” “should,” “anticipate,” “estimate,” “expect,”, “intend,” , “likely,” “objective,” “seek,” “plan,” “strive” or similar words, or the negatives of these words, identify forward-looking statements.





Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements. In addition to the other factors discussed in “ Item 1A   Risk Factors ” of our Annual Report on Form 10-K and our subsequent reports, factors that could contribute to those differences include, but are not limited to:





|  |                                                                                                                         
|- | ------------------------------------------------------------------------------------------------------------------------
|• | Our ability to fund development of our products and operations from third party financing and cash flow from operations.

|  |                                                                                                                                   
|- | ----------------------------------------------------------------------------------------------------------------------------------
|• | New product introductions by our current or future competitors could adversely affect our ability to compete in the global market.

|  |                                                                                                                                                                       
|- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
|• | The ability of our competitors with greater financial resources to develop and introduce products and services that enables them to compete more successfully than us.

|  |                                                   
|- | --------------------------------------------------
|• | The continued service of key management personnel.

|  |                                                                 
|- | ----------------------------------------------------------------
|• | Our ability to attract, motivate and retain qualified employees.

|  |                                                                                                                                                                                                                                                         
|- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|• | Changes in government laws and regulations affecting the medical device industry, sales practices, price controls, licensing and regulatory approval of new products, or changes in enforcement practices with respect to any such laws and regulations.

|  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|• | Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, or gain and maintain market approval of products, as well as the possibility of encountering infringement claims by competitors with respect to patent or other intellectual property rights, all of which can preclude or delay commercialization of a product.

|  |                                                                                                                     
|- | --------------------------------------------------------------------------------------------------------------------
|• | Potential litigation or other proceedings, including product liability and patent infringement claims adverse to us.

|  |                                                                                                                  
|- | -----------------------------------------------------------------------------------------------------------------
|• | The effects, if any, of adverse media exposure or other publicity regarding our business, products or operations.

|  |                                                                                                                                                         
|- | --------------------------------------------------------------------------------------------------------------------------------------------------------
|• | Product efficacy or safety concerns resulting in product recalls, regulatory action on the part of the FDA (or foreign counterparts) or declining sales.

|  |                                                                                                                               
|- | ------------------------------------------------------------------------------------------------------------------------------
|• | Our ability to maintain favorable supplier arrangements and relationships with manufacturers and distributors of our products.




Forward-looking statements are not guarantees of performance or results. A forward-looking statement may include a statement of the assumptions or bases underlying the forward-looking statement. We believe we have chosen these assumptions or bases in good faith and that they are reasonable. We caution you, however, that assumptions or bases almost always vary from actual results, and the differences between assumptions or bases and actual results can be material. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements in this report. These statements speak only as of the date of this report (or an earlier date to the extent applicable). We do not intend to update these statements unless applicable laws require us to do so.





20


---




Overview





MedPro Safety Products, Inc. has developed and acquired a portfolio of medical device safety products incorporating proprietary needlestick prevention technologies that deploy with minimal or no user activation.  Our strategy focuses on developing and commercializing our family of products in three related product sectors: blood collection devices, syringes for the clinical healthcare market, and intravenous devices.  Our objective for each of our products is to enter into a strategic agreement with one of more major medical product distribution firms.  We plan to continue to outsource the production of many of our products to established medical safety device manufacturers while we pursue a strategy of either developing or acquiring our own manufacturing capabilities.





Our long-term strategy is to enter into partnership agreements with major medical products distribution partners, which whenever possible would be fixed minimum volume contracts. We have entered into one such agreement for three of our products.  In addition, we are discussing the terms of a similar distribution arrangement with potential partners for a proprietary safety syringe product and a prefilled pharmaceutical safety syringe.  Our product development plans also include a needleless intravenous line based on patents and designs we control.    We have also acquired intellectual property rights to a safety needle for “pen” delivery systems for various medicaments such as insulin.





In July 2010 we entered into a six-year agreement granting rights to manufacture and distribution of our three blood collection products and providing for royalty payments based on minimum volume commitments commencing October 1, 2010.  The royalties began accruing on  October 1st and we received our first royalty payment in January 2011.





The agreement contemplates that the production and sale of our three blood collection and infusion products, and therefore the amount of revenue realized, will increase over the next several fiscal quarters. The total value of royalty payments based on minimum production volumes over the six-year term of the July 2010 agreement totals $43.75 million. We also agreed to make a marketing contribution totaling approximately $6.65 million over the six-year term of the agreement.  The July 2010 agreement was described in the Company’s Form 8-K filed July 22, 2010.





In addition to revenue commencing on our blood collection device, we have been active in the development of our prefilled and fillable safety syringes.  We have produced prototype products and packaging for our prefilled syringe and are in the process of building tools for our fillable syringe.  We are actively seeking development and distribution partners for these products.





Our financial results and operations in future periods will depend upon our ability to enter into sales and distribution agreements for our products currently under development so we can generate sustained revenues from our portfolio of products and technologies. Our operations are currently funded from the proceeds from sales of Senior Notes to which the royalty revenues from our blood collection and infusion products are committed.  In the future, we expect to use revenue from operations and borrowing from commercial lenders to supplement funding for our operations.





Senior Note Offering





On September 1, 2010, MedPro completed the issuance of $25 million principal amount of 14% Senior Secured Notes due 2016 (the “Notes”) in a private placement to institutional investors. In connection with the Note issuance, MedPro transferred all of its rights under the July 2010 agreement to receive royalties from the distribution of three safety blood collection and infusion products to a newly formed, wholly owned subsidiary, MedPro Investments, LLC (“Issuer”), which issued the Notes. The maturity date of the Notes is October 30, 2016. The Notes are obligations of the Issuer and are guaranteed by MedPro.  The Notes bear interest on the unpaid principal balance at a rate of 14% per annum. The transaction is described in the Company’s Form 8-K filed September 8, 2010.





MedPro received approximately $18,649,000 in net proceeds after the establishment of a $4,500,000 interest reserve and payment of offering expenses.  The trustee for the Notes will use the interest reserve to pay interest due prior to January 30, 2013, if royalty revenues are not sufficient to cover interest and principal payments when due.





MedPro also established and funded a $7,870,000 reserve from the net proceeds to cover potential liquidated damages payable if regulatory approval of one the blood collection products is delayed. The funds were released from the reserve on January 30, 2011 after the FDA Freedom to Practice clearance letter with respect to the Wing device was received.





We used the net proceeds to pay off all of our bank debt and all principal and accrued interest on bridge loans made by a principal shareholder, which together totaled $4,359,833.





21


---




On October 1, 2010, we received net proceeds of $4,644,587 (after payment of offering fees and expenses) from the sale of a second tranche of Notes in an aggregate principal amount of $5,000,000.





Transaction costs for both tranches of Notes totaled $2,206,858.  They consisted of fees to the investment banking firms of $1,800,000 (6%), legal fees for all parties of $362,000, expenses of $37,858 and trustee fees of $7,000.  The Company capitalized, as loan fees, the $1,800,000 investment banking fees, the trustee fee of $3,500 and the bond counsel fees of $241,000.  These costs are being amortized based on a yield method over the term of the revenue stream commencing on September 1, 2010 for six years.





The balance of the net proceeds from the both tranches of the Notes will be used for the development of our safety products and to fund ongoing operations.





Critical Accounting Estimates and Judgments





Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of our financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates. The significant accounting policies that are believed to be the most critical to fully understanding and evaluating the reported financial results include revenue recognition, inventory valuations for slow moving items, recoverability of intangible assets and the recovery of deferred income tax assets.





We recognize sales and associated cost of sales when delivery has occurred and collectability is probable. There have been minimal returns for credit, so no reserve for product returns has been established. We provide for probable uncollected amounts through a charge to earnings and a credit to the allowance for doubtful accounts based on our assessment of the current status of individual accounts.





We determine our inventory value at the lower of cost (first-in, first-out method) or market value. In the case of slow moving items, we may write down or calculate a reserve to reflect a reduced marketability for the item. The actual percentage reserved depends on the total quantity on hand, its sales history, and expected near term sales prospects. When we discontinue sales of a product, we will write down the value of inventory to an amount equal to its estimated net realizable value less all applicable disposition costs.  After writing off all remaining inventory of discontinued legacy products, the Company had no inventory of product for sale at March 31, 2011.





Our intangible assets consist principally of intellectual properties such as regulatory product approvals and patents. We currently are amortizing certain of our intangible assets using the straight line method based on an estimated economic life, after the products are introduced into the market.  We began amortization of the patents for our two blood collectors in December 2009 when these products were first introduced for human use in December.  Because our winged blood collection product, our Key-Lok technology and our Syringe Guard family of products are currently not in production for distribution, we have not begun to amortize the patents for those technologies. We expect to use the straight line method to amortize these intellectual properties over their estimated period of benefit, ranging from one to ten years, when our products are placed in full production and we can better evaluate market demand for our technology.





We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or indicate that impairment exists.  Once our intellectual property has been placed into productive service, we expect to utilize a net present value of future cash flows analysis to calculate carrying value after an impairment determination.  Our forecasted revenue on our current portfolio of intellectual property over the next five years, discounted to the balance sheet date based on our current borrowing rate, is in excess of our cost of our patents and estimated development costs ($66.6 million) by approximately 508%.





In 2010, we wrote off our Key-LokTM assets and wrote down our patent cost to 50% of its original cost.  We will continue to monitor the remaining intellectual property cost for impairment.





We have also recognized a $100,000 asset for costs incurred in connection with the development of our Winged Safety Blood Collection Set.  We are allowed to offset the first $100,000 of these costs against future product royalties.  Royalties due Visual Connections, Inc. on the first 75,000,000 units will approximate $318,000.  The Company is also entitled to reimbursement of certain costs beyond $100,000 for the Wing development.  These amounts are recoupable over the six year contract and may be settled in cash.  Costs are still being incurred and accumulated.


22


---







As part of the process of preparing our financial statements, we must estimate our actual current tax liabilities together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes.  These differences result in deferred tax assets and liabilities, which are included within the balance sheet.  We must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is not likely, a valuation allowance must be established.  To the extent we establish a valuation allowance or increase or decrease this allowance in a period, the impact will be included in the tax provision in the statement of operations.





Results of Operations for the Three Months Ended March 31, 2011 and 2010





MedPro recorded a net loss of ($2,733,561) for the three months ended March 31, 2011 , as compared to a net loss of ($3,538,710) for three months ended March 31, 2010 .  Losses from operations for the three month periods ended March 31 were $(2,090,361) for 2011 and $(3,537,186) for 2010.





Three Months Ended March 31, 2011 and 2010





Total employee compensation, including share-based compensation, for the three months ended March 31, 2011 decreased by $1,436,904 compared to the same period of 2010.  We completed the amortization of compensation costs from the August 18, 2008 employee and director options in the third quarter of 2010.  This resulted in a quarterly decrease in share-based compensation in 2011 of $1,776,250, which accounts for more than the total decline.  We also had two more employees in 2011, one engineer and one quality assistant, which, coupled with other changes, increased salary expense by approximately $54,500 in the first quarter.  The first quarter results for 2011 included a bonus approved by the Board Compensation Committee for the CEO of $253,000.  Increases in base compensation added an additional $20,750 to the first quarter.  Payroll taxes are up $11,000 from 2010 to 2011.





Promotion and investor relations expense decreased by $152,387 in the 2011 period versus the 2010 period.  Expenditures for investor relations costs declined by $167,600 relating to share-based vendor compensation that was expensed in 2010.  The remaining $15,213 increase in 2011 relates to increased investor relations activity in the first quarter of 2011.  Promotional materials were up $22,593 and other costs were down by $7,380.





Professional fees and insurance costs were down by $32,439, reflecting reduced legal costs of $51,356, reduced consulting costs of $63,061, a one-time recruiting fee of $48,000, increased insurance costs of $16,214, increased auditing and certification costs of $12,624 and various other differences of $5,140.  Factors contributing to the decrease include legal and advisory fees in 2010 related to bridge loans and outside consulting projects done in the first quarter of 2010; neither of which recurred in 2011.  Increased certification costs included work toward our CE marking in Europe in 2011 and slightly higher audit fees in 2011.





Travel costs were down by $52,994 in the first quarter of 2011 versus 2010.  The major change was a decline in airfare of $30,622, decline in car rentals of $4,525 and a decline in hotels of $18,354.  All other travel costs were up a net $507.  We were preparing for our move to our new space in the first quarter and traveled less.  We also utilized teleconferencing technology more often in 2011.





General and administrative costs were up $61,523.  Network and computer support services were up $18,304 in connection with our relocation and some continuing improvement in technology costs.  Software expense was up $11,330 relating to software renewals and acquisitions.





Filing fees were for LLC representation and association fees incurred in 2011.  Office expenses are higher due to the move and two new headcount over last year.





Depreciation and amortization were up $126,350 reflecting amortization charges on our intellectual property cost, amortization of Senior Note issuance costs and depreciation on increased equipment costs this year versus 2010.  Intellectual property amortization was $126,271 and was included in cost of revenue.  Senior Note issuance cost amortization was $123,098 and depreciation was $49,679 in 2011.  All depreciation and amortization costs totaled $172,697 in 2010.





Product development costs were up $37,431 in 2011 over 2010.  These costs reflect the Wing build and the prefilled syringe tooling and manufacturing costs.  Prefilled syringe packaging design costs were also incurred in 2011 unlike 2010.  Engineering and material costs were up $75,545.  Completed parts were down $38,084  due to the blood collection build in 2010.





23


---




During 2011, the Company wrote off  $144,114 in leasehold improvements and other fixed costs left behind at the old office and warehouse location.





Interest expense was $998,647 higher in 2011 versus 2010 primarily due to the issuance of the Senior Notes in September and October of 2010.  Interest income was $6,901 for 2010 and $5,502 for 2011.  The gain on change in fair value of derivative liabilities in 2011 was $401,297 and $42,928 in the first quarter of 2010.  The difference is attributable to the difference in the size of the derivative liabilities between periods and the inputs utilized to value the underlying derivative liabilities.  Our stock price has declined and our volatility has gone up, thereby reducing the liability.





Liquidity and Capital Resources





Total assets were $31,608,933 as of December 31, 2010 and $28,580,548 as of March 31, 2011 . The $3,028,385 decline in total assets reflects the impact of the negative cash flow from operations of ($2,413,298).  Similarly, the loss for the quarter of ($2,733,561) approximates the asset decline.





During 2011, our restricted cash decreased from $3,864,411 to $2,959,188 at March 31, 2011 , a change of $905,223.  Quarterly interest on the Senior Notes is $1,050,000.  Revenue of $150,000 was collected to offset the interest expense payment out of restricted cash.  In addition, the Company received $5,000 from the interest reserve account for servicing the loan.





Our unrestricted cash increased from $8,315,644 to $13,640,917 during the first quarter of 2011.  The reserve of $7,870,000 was released to the Company in January 2011 following the receipt of FDA clearance to market the Wing product.  The remaining $2,544,727 change in unrestricted cash represents the amount by which cash operating expenses and asset purchases exceeded cash received during the quarter.





On a net basis, our fixed asses increased $679,292 during the first quarter of 2011.  New manufacturing equipment was up $91,700.  Leasehold improvements were up $768,478 while disposals of leasehold improvements were $192,377.  Furniture and fixtures were up $59,890 while dispositions of assets in this category were $37,406 during the first quarter.  Computers were up $1,051 and dispositions were $695 in the first quarter.   The net book value of assets written off or abandoned was $144,114.





Our financial results and operations in future periods will depend upon our ability to enter into sales and distribution agreements for our other portfolio products currently under development so we can generate sustained revenues.  We plan to continue to monitor our cash position carefully.





Our July 2010 agreement for the distribution of three blood collection products provides for royalty payments based on minimum volume commitments.  We received our first quarterly royalty payment in the first quarter of 2011.  Royalty revenues are scheduled to increase over the next several fiscal quarters.  The total value of royalty payments based on minimum production volumes over the six-year term of the new agreement totals $43.75 million. We also agreed to make minimum quarterly marketing contributions totaling approximately $6.65 million over the six-year term of the agreement, payable in proportion to the volume of royalty revenues we receive.





Our sale of $30 million of Notes enabled us to monetize our right to receive royalty revenues from the sale of our blood collection products over the six-year term of the July 2010 agreement.  An interest reserve pre-funds $4.5 million of debt service on the Notes.  The royalties received from the sale of our blood collection and infusion products are committed to pay principal and interest to the Noteholders until the July 2010 agreement expires in 2016. We also retain the obligation to make quarterly marketing contributions.  We expect to use the balance of the proceeds from the sale of the Notes for working capital to fund the commercialization of our technology and expand our ability to manufacture and deliver products to commercial markets.





The net proceeds from the sale of the Notes enabled us to pay off all current bank and shareholder debt in September 2010.  During the first nine months of 2010, we had borrowed a total $2,800,000 from our principal investor, VOMF, which was bearing interest at rates of 6% and 7% per annum.  In connection with this bridge financing, we granted VOMF warrants for the purchase 325,000 shares of common stock at $4 per share and 416,672 warrants to purchase common shares at $3.00 per share.  The outstanding principal and all accrued interest on the bridge financing was paid in full on September 1, 2010.





In addition to our $13,640,917 of unrestricted cash at March 31, 2011 , we held restricted cash of $2,959,188 to service interest on our Senior Notes.





24


---




We estimate that funding our continued development and launches of our planned products, meeting current capital support requirements, and pursuing other areas of corporate interest as may be determined by the Board of Directors for the next twelve months will be covered by our existing cash resources.  Whether we commit resources to optional projects will depend upon our cash position from time to time.  Our primary cash requirements will be to fund (a) launching our blood collection products for distribution, primarily the Wing device,  (b) continuing development of our safety syringe products and other medical device safety products based on the technology for which we hold rights, and (c) increasing our administrative capability as needed to support expanded day-to-day operations.





We have projected significant development activity during 2011 and the addition of several new employees and consultants to assist with the development of our new products.  We have no bank debt to service and we have paid for all of our current technology and leasehold improvements.





Our royalty revenue from our three blood collection and infusion products is committed to pay principal and interest during the six-year term of the Notes. Until royalty revenues increase to cover all payments of principal and interest on the Notes, we expect to cover the balance due from the interest reserve.  During 2011, we estimate our cash required to fund operations will be approximately $750,000 per month.  Until we earn revenues from the sale of our other products currently under development,  we expect to fund our operations from our cash balance.  Other possible sources of funding include borrowing from commercial lenders and proceeds from the sale of securities.  Covenants in the indenture of the Senior Notes limit our ability to borrow funds during the six-year term of the Notes to $7,500,000 of new senior debt and $15,000,000 of new subordinated debt.








Item 3.  Quantitative and Qualitative Disclosures About Market Risk.





We are not party to any forwards and futures, options, swaps, or other instruments that would expose us to market risk associated with activities in derivative financial instruments, other financial instruments, and derivative commodity instruments.  Our bank indebtedness is priced at interest rates geared to the lender’s prime rate.  Therefore, our interest expense may increase or decrease due to changes in the interest rate environment.





Item 4.  Controls and Procedures.





MedPro’s management, under the supervision and with the participation of the Chief Executive Officer (the “CEO”) and Chief Financial Officer (the “CFO”), evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2011 .  Based on that evaluation, the CEO and CFO concluded that MedPro’s disclosure controls and procedures are effective in timely making known to them material information required to be disclosed in the reports filed or submitted under the Securities Exchange Act.  There were no changes in MedPro’s internal control over financial reporting during the first quarter of 2011 that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting.





Limitations on the Effectiveness of Controls





A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met.  Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with our company have been detected.  These inherent limitations include the realities that judgments in decision-making can be faulty, that breakdowns can occur because of simple errors or mistakes, and that controls can be circumvented by the acts of individuals or groups.  Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.





PART II





Item 1.  Legal Proceedings.





We are not a party to any pending legal proceedings as of this date.





Item 1A. Risk Factors





Information regarding risk factors appears our Annual Report on Form 10-K for the year ended December 31, 2010 under Item


25


---




1A – Risk Factors.  There have been no material changes from the risk factors previously discussed in our Form 10-K.





Item 2. Unregistered Sales of Equity Securities and Use of Proceeds








There were no unregistered sales of securities during the quarter ended March 31, 2011.  The following table provides certain information with respect to our purchases of common stock during the quarter ended March 31, 2011 .





PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as part of Publicly Announced Plans or ProgramsMaximum Number of Shares that May Yet Be Purchased Under the Plans or Programs1/1/2011 through 1/31/201121,777$2.51250,661749,3392/1/2011 through 2/28/201121,604$2.31272,265727,7353/1/2011 through 3/31/201126,0002.27298,265701,735Total69,381$2.36











Item 3. Default Upon Senior Securities





Not applicable.





Item 4. Reserved





Item 5. Other Information





None.


26


---










Item 6. Exhibits and Financial Statement Schedules. 3.1Amended and Restated Articles of Incorporation (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 4, 2008).3.2Bylaws (incorporated by reference to Exhibit 3.2 to Form 8-K filed on January 4, 2008).3.3Bylaw amendment dated August 10, 2009 (incorporated herein by reference to Form 8-K filed on August 17, 2008).4.1Certificate of Designations, Series A Convertible Preferred Stock Turner (incorporated by reference to Exhibit 4.1 to Amendment No. 1 on Form S-1/A (Reg. No. 333-149163) filed on July 3, 2008).4.2Form of Series A Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.3 to Form 8-K/A filed on September 10, 2007).4.3Form of Series B Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.4 to Form 8-K/A filed on September 10, 2007).4.4Series A Convertible Stock Purchase Agreement dated as of September 5, 2007 (incorporated by reference to Exhibit 4.6 to Form 10-K filed on April 18, 2008).4.5Amendment to Certificate of Designations, Series A Convertible Preferred Stock (incorporated by reference to Exhibit 4.6 to Form 10-K filed on March 30, 2009)4.6Certificate of Designations, Series B Convertible Preferred Stock (incorporated herein by reference to Exhibit 4.9 to Form 8-K filed on August 22, 2008)4.7Omnibus Amendment to Series A, B, and C Warrants held by Vision Opportunity Master Fund, Ltd. (incorporated herein by reference to Exhibit 4.10 to Form 8-K filed on August 22, 2008).4.8Certificate of Designations, Series C Convertible Preferred Stock (incorporated herein by reference to Exhibit 4.1 to Form 8-K filed on March 30, 2009).4.9Form of Common Stock Purchase Warrant held by Vision Opportunity Master Fund, Ltd. (incorporated by reference to Exhibit 4.9 to Form 10-K filed on March 30, 2010).10.1Technology Development and Option Agreement, between SGPF, LLC and MedPro Safety Products, Inc. (incorporated by reference to Exhibit 10.2 to Form 10-K filed on April 18, 2008).10.2Technology Development and Option Agreement, between SGPF, LLC and MedPro Safety Products, Inc. (incorporated by reference to Exhibit 10.2 to Form 10-K filed on April 18, 2008).10.3Amendment to Technology Development and Option Agreement, between SGPF, LLC and MedPro Safety Products, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 6, 2008).10.4Second Amendment to Technology Development and Option Agreement, between SGPF, LLC and MedPro Safety Products, Inc. (incorporated by reference to Exhibit 10.4 to Form 10-Q filed on November 15, 2010).10.5Financial Advisory Agreement dated January 11, 2010, between MedPro Safety Products, Inc and SC Capital Partners LLC. (incorporated by reference to Exhibit 10.5 to Form 10-Q filed on November 15, 2010).


27


---




10.6Medical Supply Manufacturing Agreement, dated as of July 14, 2010, between MedPro Safety Products, Inc. and Greiner Bio-One GmbH (incorporated by reference to Exhibit 10.1 to Form 10-Q filed on August 16, 2010) (portions of the exhibit have been omitted pursuant to a request for confidential treatment).10.7Purchase and Sale Agreement dated as of September 1, 2010, between MedPro Investments, LLC, and MedPro Safety Products, Inc. (incorporated by reference to Exhibit 10.7 to Form 10-Q filed on November 15, 2010).10.8Pledge and Security Agreement made by MedPro Safety Products, Inc. to U.S. Bank National Association, as Trustee, dated as of September 1, 2010. (incorporated by reference to Exhibit 10.8 to Form 10-Q filed on November 15, 2010).10.9Indenture dated as of September 1, 2010, by and between MedPro Investments, LLC, as issuer of the Notes, and U.S. Bank National Association, as initial trustee of the Notes (portions of the exhibit have been omitted pursuant to a request for confidential treatment). (incorporated by reference to Exhibit 10.9 to Form 10-Q filed on November 15, 2010).10.10Continuing Unconditional Guarantee, dated as of September 1, 2010, is made by MedPro Safety Products, Inc., to U.S. Bank National Association, as trustee under the Indenture. (incorporated by reference to Exhibit 10.10 to Form 10-Q filed on November 15, 2010).10.11MedPro Safety Products, Inc. 2008 Stock and Incentive Compensation Plan (incorporated by reference to Exhibit 10.9 to Form 8-K filed on August 22, 2008).10.12Form of Nonqualified Stock Option Award Agreement (incorporated by reference to Exhibit 10.10 to Form 8-K filed on August 22, 2008).10.13Form of Incentive Stock Option Award Agreement (incorporated by reference to Exhibit 10.13 to Form 10-K filed on March 30, 2010).10.14Employment Agreement with Marc T. Ray (incorporated by reference to Exhibit 10.1 to Form 8-K filed on April 7, 2009).10.15Employment Agreement with W. Craig Turner (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 22, 2009).10.16Employment Agreement with Agreement with Walter W. Weller (incorporated by reference to Exhibit 10.1 to Form 8-K filed on October 21, 2009).10.17Employment Agreement with Gregory C. Schupp. (incorporated by reference to Exhibit 10.17 to Form 10-K filed on March 31, 2011).10.18Employment Agreement with C. Garyen Denning. (incorporated by reference to Exhibit 10.18 to Form 10-K filed on March 31, 2011).*31.1Certification of Chief Executive Officer pursuant to SEC Rule 13(a)-14(a)*31.2Certification of Chief Financial Officer pursuant to SEC Rule 13(a)-14(a)*32.1Certification of Chief Executive Officer pursuant to Section 1350 of Chapter 63 of Title 18 of the U.S. Code*32.2Certifications of Chief Financial Officer, pursuant to Section 1350 of Chapter 63 of Title 18 of the U.S. Code


_________________________





*    Filed herewith





28


---







SIGNATURES





Pursuant to the requirements of the Securities Exchange Act if 1934, the Registrant had duly caused this amendment to be signed on its behalf by the undersigned thereunto duly authorized.





MEDPRO SAFETY PRODUCTS, INC.(Registrant)May 16, 2011By:/s/ W. Craig TurnerW. Craig TurnerChief Executive Officer, Chairman of the Board of Directors(Principal Executive Officer)
  May 16, 2011By:/s/ Marc T. RayMarc T. RayVice President Finance and Chief Financial Officer(Principal Financial and Accounting Officer)





29


---




INDEX TO EXHIBITS


The following exhibits are filed with this report.


Exhibit No.Description


31.1Certification of Chief Executive Officer pursuant to SEC Rule 13(a)-14(a)31.2Certification of Chief Financial Officer pursuant to SEC Rule 13(a)-14(a)32.1Certification of Chief Executive Officer pursuant to Section 1350 of Chapter 63 of Title 18 of the U.S. Code32.2Certifications of Chief Financial Officer, pursuant to Section 1350 of Chapter 63 of Title 18 of the U.S. Code


_________________________














30